Pfizer Inc. (NYSE:PFE) Shares Acquired by Tyler Stone Wealth Management

Tyler Stone Wealth Management increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 85.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 31,156 shares of the biopharmaceutical company’s stock after acquiring an additional 14,353 shares during the period. Tyler Stone Wealth Management’s holdings in Pfizer were worth $902,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. LGT Group Foundation grew its stake in shares of Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after purchasing an additional 18,274 shares during the period. Radnor Capital Management LLC purchased a new position in Pfizer in the third quarter valued at about $2,972,000. Kornitzer Capital Management Inc. KS boosted its position in Pfizer by 2.4% during the third quarter. Kornitzer Capital Management Inc. KS now owns 1,168,315 shares of the biopharmaceutical company’s stock worth $33,811,000 after purchasing an additional 27,562 shares in the last quarter. Capital Advisors Inc. OK grew its holdings in Pfizer by 3.5% in the third quarter. Capital Advisors Inc. OK now owns 1,439,745 shares of the biopharmaceutical company’s stock valued at $41,666,000 after purchasing an additional 48,314 shares during the last quarter. Finally, Creative Planning increased its position in shares of Pfizer by 17.1% in the third quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after buying an additional 266,167 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.32 during trading on Friday, reaching $26.72. 55,951,315 shares of the company’s stock traded hands, compared to its average volume of 37,583,031. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.60. The company has a 50 day moving average of $28.89 and a 200-day moving average of $28.63. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The stock has a market capitalization of $151.42 billion, a P/E ratio of 36.11, a price-to-earnings-growth ratio of 0.87 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the business posted ($0.17) earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.29%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.